| A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer (NCT05130060) | Mayo Clinic | 2022-01-10 |
| Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) (NCT05061017) | Diwakar Davar | 2021-12-09 |
| Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines (NCT04535401) | National Cancer Institute (NCI) | 2021-08-13 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661) | National Cancer Institute (NCI) | 2021-08-09 |
| Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer (NCT04761614) | Ning Jin | 2021-04-02 |
| Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial (NCT04693377) | M.D. Anderson Cancer Center | 2021-03-16 |
| LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer (NCT04616183) | M.D. Anderson Cancer Center | 2020-12-02 |
| SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial (NCT04599140) | M.D. Anderson Cancer Center | 2020-10-14 |
| BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment (NCT04673955) | Pierre Fabre Pharma GmbH | 2020-09-03 |
| Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab (NCT04164069) | Anne Noonan | 2020-09-02 |
| Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations (NCT04096417) | Academic and Community Cancer Research United | 2020-08-31 |
| An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response (NCT04796818) | M.D. Anderson Cancer Center | 2020-08-12 |
| Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers (NCT04221893) | University of California, San Francisco | 2020-08-07 |
| An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer (NCT03993327) | City of Hope Medical Center | 2020-07-15 |
| Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer (NCT04362839) | City of Hope Medical Center | 2020-05-27 |
| Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer (NCT03992456) | Academic and Community Cancer Research United | 2020-04-24 |
| Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer (NCT03981614) | Academic and Community Cancer Research United | 2019-10-29 |
| CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors (NCT02757391) | M.D. Anderson Cancer Center | 2019-08-09 |
| Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study (NCT04430725) | M.D. Anderson Cancer Center | 2019-08-07 |
| Intravital Microscopy in Human Solid Tumors (NCT03823144) | Mayo Clinic | 2019-02-28 |
| TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer (NCT04294264) | Rutgers, The State University of New Jersey | 2019-02-12 |
| Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer (NCT03337087) | Academic and Community Cancer Research United | 2018-11-02 |
| Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery (NCT03317119) | City of Hope Medical Center | 2018-04-11 |
| Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer (NCT03290937) | M.D. Anderson Cancer Center | 2017-12-27 |
| Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer (NCT02888743) | National Cancer Institute (NCI) | 2017-08-14 |
| Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer (NCT02873195) | Academic and Community Cancer Research United | 2017-07-07 |
| Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery (NCT02738606) | M.D. Anderson Cancer Center | 2016-09-23 |
| M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02595931) | National Cancer Institute (NCI) | 2016-07-22 |
| A Study to Estimate Overall Survival in Patients Receiving Best Supportive Care for Treatment-Resistant, Metastatic Colorectal Carcinoma (NCT03096899) | The Rogosin Institute | 2016-01-01 |
| Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (NCT02298959) | National Cancer Institute (NCI) | 2015-04-08 |
| A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer (NCT01937715) | Pfizer | 2014-02-01 |